Medical News

Two abstracts underscoring the importance of testing for BRCA1/2 mutations in women with ovary cancer were presented at this week’s Society of Gynecologic Oncologists 39th Annual Meeting on Women’s Cancers, by scientists from The University of Texas M. D. Anderson Cancer Center. In the first study, a multicenter research team led by M.D. Anderson found advanced- stage ovary cancer patients with non-Ashkenazi Jewish BRCA (non-AJ BRCA) mutations experience longer progression-free and overall survival rates in comparison to those with sporadic ovary cancer. The data confirms prior research which reported that among ovary cancer patients of Ashkenazi-Jewish heritage, BRCA1/2 mutations (AJ BRCA) are associated improved long-term survival……..

Original post by Health news from medicineworld.org

Two abstracts underscoring the importance of testing for BRCA1/2 mutations in women with ovary cancer were presented at this week’s Society of Gynecologic Oncologists 39th Annual Meeting on Women’s Cancers, by scientists from The University of Texas M. D. Anderson Cancer Center. In the first study, a multicenter research team led by M.D. Anderson found advanced- stage ovary cancer patients with non-Ashkenazi Jewish BRCA (non-AJ BRCA) mutations experience longer progression-free and overall survival rates in comparison to those with sporadic ovary cancer. The data confirms prior research which reported that among ovary cancer patients of Ashkenazi-Jewish heritage, BRCA1/2 mutations (AJ BRCA) are associated improved long-term survival……..

Original post by Health news from medicineworld.org